Developer docs
API playgroundTry for free, no card

Search company profiles

GRI Bio

Full company profile

uuid0000jkk

Namestring
GRI Bio
Legal namestring
GRI Bio, Inc.
Websiteurl
gribio.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

GRI Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in La Jolla, California and listed on NASDAQ under ticker GRI. Founded around 2015 and reorganized through a December 2022 reverse merger with Vallon Pharmaceuticals (backed by a $15 million Altium Capital investment), the company is developing an NKT cell modulator platform that targets Natural Killer T cells — innate-like lymphocytes bridging adaptive and innate immunity — to interrupt the inflammatory cascade upstream of existing therapies. The platform pairs an iNKT cell inhibitor strategy (lead asset GRI-0621, an oral RAR-β/γ selective agonist) with a dNKT cell activator strategy (GRI-0803 for systemic lupus erythematosus), backed by a library of over 500 proprietary compounds and patent coverage through 2036.

The lead clinical program, GRI-0621, is being advanced in idiopathic pulmonary fibrosis (IPF) and reported positive Phase 2a topline data in December 2025 — zero cough, 61% lower treatment-related diarrhea versus placebo, and a +99 mL FVC improvement at 12 weeks — and received FDA Orphan Drug Designation in June 2026. The pipeline also includes GRI-0803 in IND-enabling activities for SLE, plus disclosed interest in MASH/NASH and additional fibrotic indications. Composition-of-matter protection was expanded with US Patent No. 12,528,775 issued in January 2026 and a UAE patent allowance in April 2026.

GRI Bio currently generates no product revenue. Its go-to-market is structured around advancing GRI-0621 toward pivotal studies and FDA approval, with a stated intent to leverage commercialization partnerships for global distribution post-approval. Operations are funded through repeated public offerings (cumulative proceeds above $37 million since 2022) via H.C. Wainwright as exclusive placement agent, with approximately $11.0 million in cash at Q1 2026 supporting runway into Q2 2027 against a $12 million FY2025 net loss.

Short descriptiontext

GRI Bio is a clinical-stage biopharmaceutical company developing NKT cell modulator therapies — oral small molecules targeting invariant and diverse Natural Killer T cells — for inflammatory, fibrotic, and autoimmune diseases, with its lead candidate GRI-0621 in Phase 2a development for idiopathic pulmonary fibrosis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NKT cell modulators, inflammatory disease therapeutics, fibrotic disease treatments, autoimmune disease therapies, biopharmaceutical drug development
Industry1 code
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

GRI Bio is a clinical-stage biopharmaceutical company with no current product revenue. The company is developing therapies targeting NKT cells for inflammatory, fibrotic, and autoimmune diseases. GRI-0621 is in Phase 2a clinical trials for idiopathic pulmonary fibrosis (IPF), and GRI-0803 is in IND-enabling activities for systemic lupus erythematosus. Revenue will be generated from product sales upon regulatory approval and commercialization.

gribio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GRI Bio is a clinical-stage biopharmaceutical company developing oral small-molecule NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases. Its lead candidate GRI-0621 is in Phase 2a development for idiopathic pulmonary fibrosis (IPF), and GRI-0803 is advancing toward IND-enabling studies for systemic lupus erythematosus (SLE). Both candidates are drawn from a proprietary library of more than 500 NKT cell-modulating compounds.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Zero cough observed in GRI-0621 active arm vs 25% in placebo arm at 12 weeks
+5 more records
Product overview1 text field

GRI Bio is a clinical-stage biopharmaceutical company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases. The company's portfolio consists of lead program GRI-0621 (an oral RAR-βɣ dual agonist for idiopathic pulmonary fibrosis), GRI-0803 (a dNKT cell agonist for autoimmune diseases including systemic lupus erythematosus), and a proprietary library of over 500 compounds that supports ongoing pipeline expansion. The therapies are designed to target NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore immune system homeostasis.

Product and service1 record
1GRI-0621
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing novel therapies for fibrotic diseases, including IPF. Directly comparable to GRI Bio as a small-cap IPF-focused biotech with Phase 2-stage assets targeting fibrosis.

TypeDirect peer
Description

Biopharmaceutical company developing therapeutics for fibrotic diseases and cancer, with an IPF program (pamrevlumab). Comparable to GRI Bio in IPF indication focus and clinical-stage development approach.

TypeBroad incumbent
Description

Larger biopharmaceutical company with an approved IPF therapy (Tyvaso) and active pipeline in pulmonary hypertension and fibrotic lung disease. Relevant incumbent competitor in the IPF space.

4Boehringer Ingelheim
TypeBroad incumbent
Description

Global pharmaceutical company and maker of Ofev (nintedanib), the leading FDA-approved IPF therapy. Represents the dominant competitive incumbent that GRI-0621 would need to displace or complement.

TypeBroad incumbent
Description

Maker of Esbriet (pirfenidone), the other established FDA-approved IPF therapy. Major incumbent competitor with deep IPF commercial infrastructure and prescriber relationships.

6Blade Therapeutics
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing antifibrotic therapies, including lead asset cudetaxestat for IPF. Comparable to GRI Bio in target indication, stage of development, and small-cap biotech profile.

TypeDirect peer
Description

European clinical-stage biotechnology company with an IPF program (GLPG1205/ziritaxestat). Comparable to GRI Bio as a small-cap biotech targeting IPF with novel mechanisms.

TypeEmerging player
Description

Swedish clinical-stage pharmaceutical company developing buloxibutid (C21) for IPF. Comparable to GRI Bio as an emerging player in IPF with a novel mechanism of action.

9Bristol Myers Squibb
TypeBroad incumbent
Description

Major biopharmaceutical company with a broad autoimmune disease portfolio (including SLE therapies like Saphnelo). Relevant incumbent for GRI Bio's GRI-0803 dNKT program targeting systemic lupus erythematosus.

TypeBroad incumbent
Description

Global biopharmaceutical leader with established autoimmune disease franchise including therapies for SLE. Comparable as a potential strategic competitor or acquirer for GRI Bio's autoimmune pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GRI Bio

Biopharmaceutical Therapeuticsgribio.com

GRI Bio is a clinical-stage biopharmaceutical company developing NKT cell modulator therapies — oral small molecules targeting invariant and diverse Natural Killer T cells — for inflammatory, fibrotic, and autoimmune diseases, with its lead candidate GRI-0621 in Phase 2a development for idiopathic pulmonary fibrosis.

What GRI Bio does

GRI Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in La Jolla, California and listed on NASDAQ under ticker GRI. Founded around 2015 and reorganized through a December 2022 reverse merger with Vallon Pharmaceuticals (backed by a $15 million Altium Capital investment), the company is developing an NKT cell modulator platform that targets Natural Killer T cells — innate-like lymphocytes bridging adaptive and innate immunity — to interrupt the inflammatory cascade upstream of existing therapies. The platform pairs an iNKT cell inhibitor strategy (lead asset GRI-0621, an oral RAR-β/γ selective agonist) with a dNKT cell activator strategy (GRI-0803 for systemic lupus erythematosus), backed by a library of over 500 proprietary compounds and patent coverage through 2036.

The lead clinical program, GRI-0621, is being advanced in idiopathic pulmonary fibrosis (IPF) and reported positive Phase 2a topline data in December 2025 — zero cough, 61% lower treatment-related diarrhea versus placebo, and a +99 mL FVC improvement at 12 weeks — and received FDA Orphan Drug Designation in June 2026. The pipeline also includes GRI-0803 in IND-enabling activities for SLE, plus disclosed interest in MASH/NASH and additional fibrotic indications. Composition-of-matter protection was expanded with US Patent No. 12,528,775 issued in January 2026 and a UAE patent allowance in April 2026.

GRI Bio currently generates no product revenue. Its go-to-market is structured around advancing GRI-0621 toward pivotal studies and FDA approval, with a stated intent to leverage commercialization partnerships for global distribution post-approval. Operations are funded through repeated public offerings (cumulative proceeds above $37 million since 2022) via H.C. Wainwright as exclusive placement agent, with approximately $11.0 million in cash at Q1 2026 supporting runway into Q2 2027 against a $12 million FY2025 net loss.

GRI Bio firmographics

Firmographics
Name
GRI Bio
Legal name
GRI Bio, Inc.
Website
https://gribio.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
GRI Bio is a clinical-stage biopharmaceutical company developing NKT cell modulator therapies — oral small molecules targeting invariant and diverse Natural Killer T cells — for inflammatory, fibrotic, and autoimmune diseases, with its lead candidate GRI-0621 in Phase 2a development for idiopathic pulmonary fibrosis.
Ownership category
akta.pro rank

GRI Bio industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • NKT cell modulators
  • Inflammatory disease therapeutics
  • Fibrotic disease treatments
  • Autoimmune disease therapies
  • Biopharmaceutical drug development

Where GRI Bio is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

GRI Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: GRI Bio is a clinical-stage biopharmaceutical company with no current product revenue. The company is developing therapies targeting NKT cells for inflammatory, fibrotic, and autoimmune diseases. GRI-0621 is in Phase 2a clinical trials for idiopathic pulmonary fibrosis (IPF), and GRI-0803 is in IND-enabling activities for systemic lupus erythematosus. Revenue will be generated from product sales upon regulatory approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

GRI Bio product offering

Product offering

Core offering

GRI Bio is a clinical-stage biopharmaceutical company developing oral small-molecule NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases. Its lead candidate GRI-0621 is in Phase 2a development for idiopathic pulmonary fibrosis (IPF), and GRI-0803 is advancing toward IND-enabling studies for systemic lupus erythematosus (SLE). Both candidates are drawn from a proprietary library of more than 500 NKT cell-modulating compounds.

Product overview

GRI Bio is a clinical-stage biopharmaceutical company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases. The company's portfolio consists of lead program GRI-0621 (an oral RAR-βɣ dual agonist for idiopathic pulmonary fibrosis), GRI-0803 (a dNKT cell agonist for autoimmune diseases including systemic lupus erythematosus), and a proprietary library of over 500 compounds that supports ongoing pipeline expansion. The therapies are designed to target NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore immune system homeostasis.

Differentiator

Problem solved

Functional benefit

Products and services

  • GRI-0621

Quantifiable outcome

  • Zero cough observed in GRI-0621 active arm vs 25% in placebo arm at 12 weeks
  • +5 more outcomes

Companies that use GRI Bio

Customer profile

Segments1 record

Ideal customer profiles2 records

GRI Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

GRI Bio partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

GRI Bio competitors and assessment

Company assessment

Direct peers

  • Pliant Therapeutics: Clinical-stage biopharmaceutical company developing novel therapies for fibrotic diseases, including IPF. Directly comparable to GRI Bio as a small-cap IPF-focused biotech with Phase 2-stage assets targeting fibrosis.
  • FibroGen: Biopharmaceutical company developing therapeutics for fibrotic diseases and cancer, with an IPF program (pamrevlumab). Comparable to GRI Bio in IPF indication focus and clinical-stage development approach.
  • Blade Therapeutics: Clinical-stage biopharmaceutical company developing antifibrotic therapies, including lead asset cudetaxestat for IPF. Comparable to GRI Bio in target indication, stage of development, and small-cap biotech profile.
  • Galapagos NV: European clinical-stage biotechnology company with an IPF program (GLPG1205/ziritaxestat). Comparable to GRI Bio as a small-cap biotech targeting IPF with novel mechanisms.

Broad incumbents

  • United Therapeutics: Larger biopharmaceutical company with an approved IPF therapy (Tyvaso) and active pipeline in pulmonary hypertension and fibrotic lung disease. Relevant incumbent competitor in the IPF space.
  • Boehringer Ingelheim: Global pharmaceutical company and maker of Ofev (nintedanib), the leading FDA-approved IPF therapy. Represents the dominant competitive incumbent that GRI-0621 would need to displace or complement.
  • Roche / Genentech: Maker of Esbriet (pirfenidone), the other established FDA-approved IPF therapy. Major incumbent competitor with deep IPF commercial infrastructure and prescriber relationships.
  • Bristol Myers Squibb: Major biopharmaceutical company with a broad autoimmune disease portfolio (including SLE therapies like Saphnelo). Relevant incumbent for GRI Bio's GRI-0803 dNKT program targeting systemic lupus erythematosus.
  • AbbVie: Global biopharmaceutical leader with established autoimmune disease franchise including therapies for SLE. Comparable as a potential strategic competitor or acquirer for GRI Bio's autoimmune pipeline.

Emerging players

  • Vicore Pharma: Swedish clinical-stage pharmaceutical company developing buloxibutid (C21) for IPF. Comparable to GRI Bio as an emerging player in IPF with a novel mechanism of action.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

GRI Bio social profiles

Digital presence

GRI Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GRI Bio leadership team

Management profile

Number of profiles

Profiles9 records

GRI Bio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GRI Bio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GRI Bio

What does GRI Bio do?

GRI Bio is a clinical-stage biopharmaceutical company developing oral small-molecule NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases. Its lead candidate GRI-0621 is in Phase 2a development for idiopathic pulmonary fibrosis (IPF), and GRI-0803 is advancing toward IND-enabling studies for systemic lupus erythematosus (SLE). Both candidates are drawn from a proprietary library of more than 500 NKT cell-modulating compounds.

Is GRI Bio a public or private company?

GRI Bio is a public company. It is classified as public and is currently operating.

When was GRI Bio founded?

GRI Bio was founded in 2015. It employs 1 to 10 people.

Where is GRI Bio based?

GRI Bio is headquartered in San Diego, United States, in the North America region.

How does GRI Bio make money?

One revenue line is on record: drug Development and Commercialization.

Who are GRI Bio's main competitors?

Direct peers on record are Pliant Therapeutics, FibroGen, Blade Therapeutics and Galapagos NV. Broad incumbents are United Therapeutics, Boehringer Ingelheim, Roche / Genentech, Bristol Myers Squibb and AbbVie. Vicore Pharma is listed as an emerging player.

Does GRI Bio have an API?

No public API is recorded for GRI Bio.

What industry is GRI Bio in?

GRI Bio's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialPrimary Sclerosing Cholangitis Drugs In Development 2026: Pipeline Therapies, Ongoing Trials, And Companies Driving Innovation Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade PharmaPrimary sclerosing cholangitis (PSC) pipeline therapies are advancing, with Mirum's volixibat achieving a primary endpoint in its Phase IIb VISTAS trial and receiving FDA Breakthrough and Orphan Drug designations. Other candidates include norucholic acid, nebokitug, and elafibranor, with several companies planning Phase III trials or regulatory filings in 2026-2027.Stock TitanGRI Bio to Present Phase 2a Insights at IPF SummitGRI Bio's CEO Marc Hertz and CSO Vipin Kumar will present at the 10th IPF Summit in Boston, September 29–October 1, 2026. The presentations cover immune biology and Phase 2a development of GRI-0621, an oral RARβ/γ-selective agonist for idiopathic pulmonary fibrosis. The company cites encouraging Phase 2a findings across lung function, biomarkers, and tolerability.BioSpaceGRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF SummitGRI Bio's CEO Marc Hertz and CSO Vipin Kumar will present at the 10th IPF Summit in Boston from September 29 to October 1, 2026. The talks cover immune biology in IPF and Phase 2a data for GRI-0621, an oral RARβ/γ-selective agonist. The company expects to share insights on lung function, biomarkers, and tolerability.YahooGRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?GRI Bio, Inc. was upgraded to a Zacks Rank #2 (Buy) rating, reflecting rising earnings estimates. The upgrade signals an improved earnings outlook that could drive buying pressure and a higher stock price. The Zacks system tracks consensus EPS estimates to gauge near-term price movements.AInvestGRI Bio Ignites with 22% Surge: A Volatile Breakout Defying the Biotech LullGRI Bio surged 22% intraday, closing at $2.44 with 63.8% turnover, as price breached the $2.50 resistance and held above the 200-day moving average. The move defies sector weakness, with Moderna down 2.67%, and the breakout is driven by technical factors rather than company news. Traders should watch for a sustained close above $2.50 to confirm continuation.YahooGRI Bio Featured in "Why Now" On-Demand Video WebcastGRI Bio, Inc. announced on August 27, 2026 that it is featured in a "Why Now" video webcast, in which CEO Marc Hertz, Ph.D. discusses its IPF treatment GRI-0621, a once-daily oral RARβ/γ-selective agonist. The company is also presenting data on GRI-0621 at the 2026 European Respiratory Society Congress in Barcelona, September 5-9.Stock TitanGRI Bio Lung Fibrosis Treatment in On-Demand WebcastGRI Bio, Inc. announced on August 27, 2026 that it is featured in a "Why Now" video webcast, in which CEO Marc Hertz, Ph.D. discusses its IPF treatment GRI-0621, a once-daily oral RARβ/γ-selective agonist. The company said it will present data supporting GRI-0621's mechanism at the 2026 European Respiratory Society Congress in Barcelona, September 5-9.BioSpaceGRI Bio Featured in “Why Now” On-Demand Video WebcastGRI Bio's CEO Marc Hertz discussed its IPF drug GRI-0621 in a "Why Now" webcast, highlighting its differentiated mechanism and unmet need. The company will present data on GRI-0621 at the 2026 ERS Congress in Barcelona.Stock TitanGRI Bio to Present Phase 2a IPF Data at ERS 2026GRI Bio announced that data from its Phase 2a study of the drug GRI-0621 for idiopathic pulmonary fibrosis (IPF) will be presented at the 2026 European Respiratory Society Congress. The presentations highlight encouraging signals regarding lung function improvement, anti-fibrotic biomarkers, and favorable tolerability of the therapy. These findings support the company's conviction in the drug's potential to advance the treatment landscape for IPF patients.TradingViewGRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026GRI Bio announced that three abstracts and an oral presentation on its Phase 2a GRI-0621-IPF-02 study will be presented at the 2026 ERS Congress in Barcelona. The data highlight lung function, anti-fibrotic biomarkers, and favorable tolerability in idiopathic pulmonary fibrosis patients.